Clinical trial
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With…
NCT00041067 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00041067 |
|---|---|
| Title | S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer |
| Official title | Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, trastuzumab, docetaxel, vinorelbine |
| Enrollment | 76 |
| Start date | Sep 1, 2002 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: